

ASX Market Announcements
ASX Limited
Level 4
North Tower, Rialto
525 Collins Street
Melbourne VIC 3000

**RE: PRESENTATION AT EBD BIOTECH SHOWCASE, SAN FRANCISCO, JANUARY 11
2016**

Please see attached announcement notifying shareholders of the presentation by Adherium Group CEO, Garth Sutherland, at the upcoming EBD Biotech Showcase in San Francisco.

Kind regards



Bronwyn Le Grice
Joint Company Secretary

[ASX: ADR](#)

ABN
24 605 352 510

Company Overview

Adherium is a global leader in digital health technologies which address sub optimal medication use in chronic disease.

Directors

Dr J Doug Wilson (Chair)
Mr Garth Sutherland (Group CEO)
Prof. John Mills
Mr Jeremy Curnock Cook
Mr Bruce McHarrie
Mr Bryan Mogridge
Dr William (Bill) Hunter

Joint Company Secretaries

Mr Rob Turnbull
Ms Bronwyn Le Grice

Registered Office

Level 12, 15 William Street
Melbourne VIC 3000
Australia

NZ Office

Level 2, 204 Quay Street
Auckland 1010
New Zealand

Investor Relations Contact

Ms Bronwyn Le Grice
+61 424 862 600

Email

investors@adherium.com

Website

www.adherium.com

Adherium to Present Corporate Overview at Biotech Showcase 2016

Melbourne, Australia, January 5 2016: Adherium Limited (ASX: ADR), a global leader in digital health technologies which address sub-optimal medication use in chronic disease, will present a corporate overview at the EBD Biotech Showcase Conference, taking place in San Francisco between 11-13 January 2016.

San Francisco in January each year sees the largest global gathering of life sciences and healthcare investors and analysts, together with company executives across a number of parallel conferences and private meetings.

Adherium's company presentation during which it will provide an overview of 2015 and future directions for the Company will take place in Room Mission II at 9.00 a.m. on Monday 11 January. Further information, please see <http://www.ebdgroup.com/bts/index.php>

****ENDS****

ABOUT ADHERIUM

Adherium (ASX:ADR) is an Australian Securities Exchange listed company which develops, manufactures and supplies digital health technologies which address sub-optimal medication use and improve health outcomes in chronic disease.

Adherium is a provider of digital health solutions to pharmaceutical, remote patient monitoring and clinical trials companies and organisations. The Company's proprietary Smartinhaler™ platform has been independently proven to improve medication adherence and health outcomes for patients with chronic respiratory disease. Adherium has the broadest range of "smart" medication sensors for respiratory medications globally.

Clinical outcomes data has proven that the Smartinhaler platform can improve adherence by up to 59% in adults and 180% in children and reduce severe episodes by 60% in adults. In addition, interim data from a study at the University of Sheffield demonstrated a 144% increase in adherence, a restoration of lung function to 100% and a 37% reduction in oral steroids indicating reduced severe exacerbations in children. Both children and adults benefit from improved quality-of-life as a result of their improved adherence, demonstrating a substantial gain over current best practice treatment.

The Smartinhaler™ platform has so far been used in 63 projects (clinical, device validation or other) and has been referenced in 33 peer reviewed journal articles. The Company has received FDA 510(k) notifications for clearance to market and CE Marks for its devices and software, which allows it to sell these devices into international markets.

www.smartinhaler.com
www.adherium.com

Enquiries:

At the Company	Media enquiries
Bronwyn Le Grice Head of Commercial Development & Corporate Affairs M +61 (0)424 862 600 E: bronwynlg@adherium.com	EU Media Sue Charles / Gemma Howe Instinctif Partners D +44 (0)20 7866 7860 E: sue.charles@instinctif.com gemma.howe@instinctif.com AU/NZ/ Media Rudi Michelson Monsoon Communications D +61 (0)3 9620 3333 E rudim@monsoon.com.au